Cryoport, Inc.
(NASDAQ: CYRX) has developed one of the most comprehensive solution platforms
available today in the life sciences-focused cryogenic logistics space, with a
suite of proprietary technologies such as its signature Cryoport Express®
(http://dtn.fm/jGrs5) dry vapor dewars for materials that need to be kept at
frozen temperatures, as well as its Cryoportal™ logistics management platform
and SmartPak II™ continuous, geo-sensing monitoring system
(http://dtn.fm/53nP7). Reinforced by a rock-solid commitment to 24/7 customer
support and cold chain logistics consulting spanning risk assessment, lane
qualification and process flow – the company’s portfolio of industry-leading
technologies has propelled CYRX to the forefront of the sector, allowing the company
to secure such sweetheart deals as the recent strategic partnership with $2.4
billion market cap, diversified metals manufacturing giant, Worthington
Industries (NYSE: WOR).
This latest deal
will see Worthington’s CryoScience by Taylor Wharton Division, one of the most
influential and competent manufacturers in the space today, designing and
manufacturing biostorage and logistics hardware for CYRX’s life sciences
solutions. It’s the kind of cozy deal that will open big doors for the company,
granting its already much sought after cold chain logistics solutions the
ability to satisfy a much broader client mix, and enabling the company to
dynamically scale support for proliferating client commercialization efforts.
Cryoport is no
stranger to marching into the gap like this, as news of the Worthington
partnership came just days after the company’s announcement on April 11
regarding the launch of its new Temperature Controlled Logistics Consulting
Division, which was organized to answer feverish demand from a global and
burgeoning cellular-based therapies market. The deluge of cell-based
immunotherapy technologies currently in the soon-to-be $2.45 trillion-plus
personalized medicine pipeline (http://dtn.fm/rm0Kj) has created a perfect
storm for storage and transportation logistics players and only a tiny handful
of key players, such as CYRX, are positioned to capitalize on runaway demand
for the kind of planning and strategies needed to help effectively develop and
deploy temperature sensitive/personalized therapies.
The broader global
cryogenic equipment market is on-track to hit upwards of $25 billion by 2022
(http://dtn.fm/VwY57), with the Asia-Pacific region seen as the strongest
segment at around $7.83 billion projected by 2019 (http://dtn.fm/sa9FD). This
is a target-rich environment for a company like Cryoport, which is actively
working in regenerative medicine in support of some 64 different clinical
trials, including Perseus PCI’s Phase II2b melanoma and ovarian cancer clinical
trial, as well as ImmunoCellular Therapeutics’ (NYSE: IMUC) registrational
Phase III clinical trial of ICT-107 immunotherapy in aggressive brain cancer,
which spans 400-plus newly-diagnosed glioblastoma patients at 120 sites
throughout North America and Europe.
Any questions as to
just how capable Cryoport is when it comes to securing additional traction
within the space, should be quickly put to rest by one look at the company’s
earlier deal in March of 2016 with one of the planet’s undisputed leaders in
logistics, UPS (NYSE: UPS). UPS launching its biotech, pharma and medical
device industry-tailored Temperature True® Cryo solution in Europe, which
allows customers to keep products at -150°C for 10 days using Cryoport Express
containers’ dry vapor liquid nitrogen technology, gives CYRX access to the
global network of 51 UPS healthcare-dedicated facilities, and sets the company
up for continued success alongside UPS, which serves more than 220 countries
and territories worldwide.
For more
information, visit www.cryoport.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
